PGC1α expression is controlled in skeletal muscles by PPARβ, whose ablation results in fiber-type switching, obesity, and type 2 diabetes  by Schuler, Michael et al.
S H O R T A R T I C L EPGC1a expression is controlled in skeletal muscles by PPARb,
whose ablation results in fiber-type switching, obesity, and type
2 diabetes
Michael Schuler,1,2,3,4,5,6 Faisal Ali,1,2,3,4,5 Ce´line Chambon,1,2,3,4,5 Delphine Duteil,1,2,3,4,5 Jean-Marc Bornert,1,2,3,4,5
Aubry Tardivel,7 Be´atrice Desvergne,7 Walter Wahli,7 Pierre Chambon,1,2,3,4,5,6,* and Daniel Metzger1,2,3,4,5,6,*
1 IGBMC (Institut de Ge´ne´tique et de Biologie Mole´culaire et Cellulaire), Department of Physiological Genetics
2 Inserm, U596
3 CNRS, UMR7104
4 Colle`ge de France
Illkirch, F-67400 France
5 Universite´ Louis Pasteur, Strasbourg, F-67000 France
6 Institut Clinique de la Souris, 67404, Illkirch, Strasbourg, France
7 Center for Integrative Genomics, National Center of Competence in Research ‘‘Frontiers in Genetics,’’ University of Lausanne,
CH-1015 Lausanne, Switzerland
*Correspondence: metzger@igbmc.u-strasbg.fr (D.M.), chambon@igbmc.u-strasbg.fr (P.C.)
Summary
Mice in which peroxisome proliferator-activated receptor b (PPARb) is selectively ablated in skeletal muscle myocytes were
generated to elucidate the role played by PPARb signaling in thesemyocytes. These somaticmutantmice exhibited amuscle
fiber-type switching toward lower oxidative capacity that preceded the development of obesity and diabetes, thus demon-
strating that PPARb is instrumental in myocytes to the maintenance of oxidative fibers and that fiber-type switching is likely
to be the cause and not the consequence of thesemetabolic disorders.We also show that PPARb stimulates inmyocytes the
expression of PGC1a, a coactivator of various transcription factors, known to play an important role in slow muscle fiber
formation. Moreover, as the PGC1a promoter contains a PPAR response element, the effect of PPARb on the formation
and/or maintenance of slowmuscle fibers can be ascribed, at least in part, to a stimulation of PGC1a expression at the tran-
scriptional level.Introduction
Skeletal muscles account for up to 55% of total body mass in
nonobese mammals and generate motile forces and heat.
They are a major site for carbohydrate and fatty acid metabolism
and are composed of three myofiber types exhibiting distinct
contractile and metabolic properties: (1) slow-twitch, oxidative,
fatigue-resistant, oxidative (SO) fibers, (2) fast-twitch, oxidative-
glycolytic (FOG) fibers, and (3) fast-twitch, glycolytic, fatigue-
able (FG) fibers. These fiber types are established during devel-
opment, and in adults, they display a remarkable adaptation to
functional and metabolic demands, responding by a fiber-type
switching to altered workload and frequency of motor nerve
stimulation (Berchtold et al. [2000]; Fluck and Hoppeler [2003],
and references therein). Moreover, caloric restriction retards
age-related slow-to-fast fiber-type conversion in rats (Aspnes
et al., 1997), and studies of humans and rodents have indicated
a correlation between (1) obesity and/or diabetes and (2) re-
duced muscle oxidative capacity and/or fiber type composition.
However, it is not known whether replacement of oxidative fi-
bers by glycolytic fibers is a cause or a consequence of obesity
or diabetes (Patti et al. [2003], Petersen et al. [2003], Tanner et al.
[2002], Wisloff et al. [2005], and references therein).
Peroxisome proliferator-activated receptors (PPARs) are
members of the nuclear receptor superfamily that form hetero-
dimers with retinoid X receptors (RXRs) and bind preferentiallyCELL METABOLISM 4, 407–414, NOVEMBER 2006 ª2006 ELSEVIER Ito direct repeats of the consensus hexameric nucleotide
sequence 50-AGGTCA-30 separated by 1 base (DR1), called
peroxisome proliferator-activated receptor response elements
(PPREs), to control target gene expression. Three PPAR iso-
types (a, b, and g), with distinct tissue distribution, have been
identified. PPARa (NR1C1) is preferentially expressed in tissues
with high fatty acid (FA) oxidation, such as heart, kidney, brown
adipose tissue (BAT), and liver, where it regulates FA transport,
esterification and oxidation via transcriptional activation of
genes encoding enzymes involved in each step of FA break-
down. PPARg (NR1C3) is predominant in adipose tissue and
plays an essential role in adipocyte differentiation and survival
(Desvergne and Wahli, 1999; Evans et al., 2004; Metzger et al.,
2005). In contrast, PPARb (d; NR1C2), which is expressed ubiq-
uitously, is the most abundant PPAR isotype in skeletal muscle
(Escher et al., 2001). Increases of PPARb activity through ligand
activation, PPARb overexpression, or expression of a constitu-
tively active PPARb in transgenic mice, have recently suggested
that this receptor could be physiologically involved in fatty acid
metabolism and muscle fiber-type switching (Evans et al., 2004).
To investigate whether PPARb is actually a key player in these
processes, we have generated PPARbskm2/2 mice, in which
PPARb is selectively ablated in skeletal muscle myocytes. We
show that these mice exhibit a functional switch of the skeletal
muscle fiber type toward lower oxidative capacity that precedes
the appearance of age-dependent obesity and type 2 diabetes.NC. DOI 10.1016/j.cmet.2006.10.003 407
S H O R T A R T I C L EFigure 1. Characterization of PPARb-deficient skeletal muscles
A) Relative weight of fast (G, gastrocnemius), slow (S, soleus) and mixed (T, tibialis) muscles from 28 week-old CT and MT mice (n = 6–8).
B) Histochemical NADH-tetrazolium reductase staining of tibialis muscles of 28 week-old CT (a) and PPARbskm2/2 (b) mice, and 20 week-old CT (c) and PPARb(i)skm2/2 (d)
mice. Three different fiber types are distinguished: oxidative (SO) and intermediate (FOG) fibers are darkly and moderately stained, respectively; glycolytic fibers (FG) are
unstained. Scale bar, 100 mm.
C) Percentage of unstained fibers in tibialis muscles of 12 and 28 week-old CT and MT mice (n = 4–6).
D) Biochemical determination of CS, b-HAD, and LDH activities in tibialis extracts of 12 week-old CT and PPARbskm2/2 (MT) mice (n = 4).
E) Relative MHCI and MHCIIb transcript levels in gastrocnemius muscle of 16 week-old CT and MT mice.
F) Relative troponin I slow and fast transcript levels in gastrocnemius muscle of 16 week-old CT and MT mice.
G) Relative transcript levels in gastrocnemius muscle of 10–12 week-old CT and MT mice of genes involved in FA metabolism and energy uncoupling (UCP 3). LPL, lipo-
protein lipase; FAT/CD36, fatty acid translocase; hFABP, heart fatty-acid binding protein; LCAS, long chain acyl-CoA synthetase; LCAD, MCAD, and SCAD, long-,
medium-, and short-chain acyl-CoA dehydrogenase; b-HAD, b-hydroxy-acyl-CoA dehydrogenase; CS, citrate synthase.
H) Relative transcript levels of genes involved in glucose metabolism. PFK, phosphofructokinase 1; GLUT4, glucose transporter 4.
I) Relative transcript levels of genes of the mitochondrial electron transport chain and of transcription factors controlling their expression, as indicated (n = 7–11).We also demonstrate that the expression of PGC1a, a transcrip-
tional coregulator that coordinates the formation/maintenance
of slow fibers in skeletal myocytes, is directly controlled by
PPARb.
Results
To selectively ablate PPARb in skeletal muscle, PPARbL2/L2
mice bearing floxed PPARb L2 alleles (in which LoxP sites flank
the PPARb exon encoding the N-terminal zinc finger of the DNA
binding domain) were bred with HSA-Cretg/0 mice that express408the Cre recombinase under the control of the human a-skeletal
actin promoter (Miniou et al., 1999) to produce control mice
(CT) as well as HSA-Cretg/0/PPARbL2/L2 somatic mutants (MT)
in which PPARb is selectively ablated in skeletal muscles
(PPARbskm2/2 mice; Supplemental Data).
Muscle-to-body weight ratios and the morphology of gastroc-
nemius (G), soleus (S), and tibialis (T) muscles were similar in 12
and 28 week-old CT and MT (Figure 1A and data not shown).
However, histochemical staining with NADH-tetrazolium reduc-
tase, a marker of the mitochondrial respiratory chain complex I
activity, revealed a 40% increase of unstained FG in tibialisCELL METABOLISM : NOVEMBER 2006
PPARb function in skeletal muscles of the mousemuscles of 12 week-old MT mice (MT, 35%; CT, 25%), and
a corresponding lower number of stained fibers (FOG and SO;
Figure 1B, panels a and b), indicating that muscle fibers in MT
were less oxidative than in CT. In 28 week-old MT, the percent-
age of NADH-tetrazolium reductase unstained fibers was further
increased to reach 45%, whereas it was unchanged in CT
(Figure 1C), showing an age-dependent decrease of oxidative
capacity in PPARb-deficient skeletal muscles. Interestingly, se-
lective ablation of PPARb in skeletal muscles of adult mice
[PPARb(i)skm2/2 mice], induced by Tamoxifen administration to
PPARbL2/L2 mice bearing the HSA-Cre-ERT2 transgene (Schuler
et al., 2005), also resulted in a lower oxidative capacity of skel-
etal muscle (Figure 1B, compare panels c and d).
To further characterize muscle oxidative capability, enzyme
activities of the aerobic oxidative pathways (fatty acid oxidation
and tricarboxylic acid cycle [TCA]) and of the glycolytic path-
ways were analyzed in tibialis muscle extracts of 12 week-old
mice. The activity of b-hydroxy-acyl-CoA dehydrogenase (b-
HAD, aerobic-oxidative pathway, FA oxidation) and citrate syn-
thase (CS, aerobic-oxidative pathway, TCA) were 50% lower in
MT than CT, whereas the activity of the glycolytic enzyme lac-
tate dehydrogenase (LDH) was unchanged (Figure 1D; data
not shown). To determine the fiber-type composition, the ex-
pression of myosin heavy chain (MHC) isoforms was analyzed
in gastrocnemius of 16 week-old mice by quantitative RT-
PCR. The transcript levels of the slow MHCI was w50% lower
in MT than in CT, whereas those of fast MHCIIb were w25%
higher in MT (Figure 1E). Moreover, Troponin I slow RNA levels
were reduced by w35% in MT, whereas those of troponin I
fast were increased byw20% in MT (Figure 1F).
Quantitative RT-PCR analysis of 10–12 week-old mouse gas-
trocnemius muscle revealed that transcript levels of genes con-
trolling (1) lipolysis (LPL); (2) FA uptake (FAT/CD36), binding
(hFABP), activation (LCAS), and b-oxidation (LCAD, MCAD,
SCAD, b-HAD); and (3) the TCA cycle (CS) were 20%–40% lower
in MT. Moreover, the transcript level of uncoupling protein (UCP)
3, a putative target of PPARb-specific ligands in skeletal muscle
cells (Muoio et al., 2002), was 50% lower in MT (Figure 1G),
whereas those of two genes of the glycolytic pathway (PFK
and GLUT4) were similar in CT and MT (Figure 1H).
As the histochemically determined mitochondrial respiratory
chain complex I activity was lower in MT than in CT (Figures
1B and 1C), we also analyzed the transcript levels of nuclear
genes encoding components of the respiratory chain. The tran-
scripts of Ndfua2, Ndfub3, Ndfub5, Ndfus2, and Ndfus3 (com-
plex I); Sdhb (complex II); Uqcrc1 (complex III); Cox5b and
Cox6a2 (complex IV); as well as Atp5l and Atp5o (complex V)
were 20%–40% lower in MT. Moreover, the transcript level of
the mitochondrial transcription factor A (mtTFA), which regu-
lates transcription of mitochondrial genes encoding respiratory
chain proteins, was 20% lower in the MT gastrocnemius mus-
cles, and the RNA level of the mitochondrial Cox 2 gene was
reduced by about 20% in MT (Figure 1I). Interestingly, the
transcript level of PGC1a, which binds and coactivates the
transcriptional function of nuclear respiratory factor-1 (NRF-1)
on the mtTFA promoter (Wu et al., 1999), was 2-fold lower in
MT than in CT (Figure 1I), whereas those of NRF-1 were un-
changed. Gastrocnemius mitochondrial DNA content was how-
ever similar in CT and MT at 8 and 26 weeks (data not shown).
Note that transcript levels of UCP1, 2, and 3 and PPARa in
BAT; those of leptin, FAS, SREBP-1, and PPARg in white adi-CELL METABOLISM : NOVEMBER 2006pose tissue (WAT); and those of MCAD and PPARa in liver
were similar in CT and MT (data not shown). Taken together,
these data show that the transcript levels of many genes in-
volved in FA metabolism, as well as of a number of nuclear
and mitochondrial genes encoding components of the mito-
chondrial electron transport chain, were selectively reduced in
PPARbskm2/2 mouse skeletal muscles whose fibers were
shifted toward a more fast-twitch, glycolytic type.
As skeletal muscle oxidative capacity decreased with time in
PPARbskm2/2 mice, we subjected 43 week-old mice to endur-
ance exercise performance tests. The treadmill running time
and distance until exhaustion wasw30% lower in PPARbskm2/2
than in CT (Figure S2). These reductions in MT were not due to
greater body weight of MT, as similar variations in endurance
performance tests were observed with weight-matched CT
and MT (data not shown). In contrast, spontaneous locomotor
activity (determined with an open field test) was similar in CT
and MT (data not shown). Thus, the lower number of slow oxida-
tive fibers in MT resulted in markedly reduced capacity to sustain
running exercise.
The decrease in PGC1a transcripts in PPARbskm2/2 muscles
prompted us to investigate whether PPARb might directly con-
trol PGC1a expression. Sequence analysis of the PGC1a pro-
moter revealed a conserved putative PPRE (50-AGGACA A
AGGTCA-30), located between nucleotides 2024 and 2043 and
between nucleotides 1872 and 1891, upstream of the mouse
(m) and human (h) PGC1a transcriptional initiation site, respec-
tively (Figure 2A). Electrophoretic mobility shift assays showed
that PPARb/RXRa heterodimers efficiently bound the PGC1a
PPRE; no binding could be observed when it was mutated in
its 30 and 50 repeated motifs (PGC1a PPREm; Figure 2B, com-
pare lanes 1 and 2), and PPARb/RXRa binding to PGC1a
PPRE was efficiently competed out with an excess of unlabeled
wild-type PPRE but not with PGC1a PPREm (Figure 2B; lanes
3–6 and 7–10). Moreover, treatment of C2C12 myocytes with
the PPARb-selective agonist GW501516 (Oliver et al., 2001)
and the RXR selective agonist BMS649 (Roy et al., 1995) in-
duced PGC1a transcripts by 4-fold (Figure 2C). To support
the possibility that PPARb could control the activity of PGC1a
promoter in muscle cells, C2C12 myoblasts were transiently
transfected with a luciferase reporter gene (pGL-PGC1a) driven
by a 4 kb mouse PGC1a promoter/enhancer region and differ-
entiated into myocytes. Addition of the PPARb-specific agonist
GW501516 stimulated luciferase activity 2-fold, and this ligand-
dependent stimulation of PGC1a promoter activity was abol-
ished when its PPRE was mutated (pGL-PGC1am; Figure 2D).
In contrast, the PPARg-selective ligand rosiglitazone stimulated
the PGC1a promoter activity only 1.2-fold, and the PPARa-
selective ligand WY14643 had no effect (Figure 2D). Thus,
PGC1a promoter activity can be enhanced by liganded PPARb
in muscle cells via a PPRE located between nucleotides 2024
and 2043 upstream of the mouse PGC1a start site.
Food intake and basal metabolic rate were similar in CT and
MT (data not shown). However, PPARbskm2/2mice fed a regular
diet gained more weight than CT (Figures 3A and 3B; data not
shown); 28 week-old PPARbskm2/2 mice were 5.5 g heavier
than CT mice. This difference was not due to increased muscle
weight (Figure 1A), but to increased body fat content and WAT
weight (Figures 3C and 3D). Histological analysis of epidydimal
fat pad revealed that adipocytes were hypertrophic in 28 week-
old obese PPARbskm2/2 mice (Figure 3E), indicating that409
S H O R T A R T I C L EFigure 2. Functional characterization of the PGC1a-
PPRE
A) Sequence of the consensus, wild-type human and
mouse, and mutated PGC1a-PPRE.
B) Electrophoretic mobility shift assay (EMSA) of
radiolabeled PGC1a PPRE using PPARb and RXRa.
In vitro synthesized nuclear receptors were incu-
bated with the wild-type (lanes 1 and 3–10) and mu-
tant (lane 2) PGC1a PPRE (PGC1a PPREm), in the
absence (lanes 1–3 and 7) or presence of increasing
concentrations of unlabeled PGC1a PPRE (lane 4–
6) or PGC1a PPREm (lane 8–10).
C) Relative PGC1a transcript levels in C2C12 myo-
cytes treated with vehicle or GW501516 and
BMS649 (GW + BMS) (n = 3).
D) Luciferase activity was determined on C2C12
myoblast transfected with pGL3-basic, pGL-
PGC1a, or pGL-PGC1am luciferase reporter vectors,
and grown in the absence or presence of GW501516
(GW), WY14643 (WY), or rosiglitazone (rosi). Data are
expressed as mean values 6 SEM, relative to vehi-
cle-treated pGL3-transfected cells.impaired muscular FA breakdown in PPARbskm2/2 animals
leads to increased fatty acid storage in adipose tissue. Serum
glucose, insulin, and triglyceride levels after a 6 hr fast were
1.2-, 1.8-, and 1.4-fold higher in 12 week-old MT than in CT
mice, respectively (Figure 4A), and circulating nonesterified
free fatty acid levels were slightly increased in MT (1.1-fold,
which did not reach statistical significance; data not shown).
Moreover, insulin efficiently decreased glucose levels in these
mice when subjected to an intraperitoneal insulin tolerance
test (Figure 4B). However, 8 month-old MT mice were insulin-
resistant and glucose-intolerant (Figures 4C and 4D), indicating
that mice lacking PPARb in skeletal muscles develop an age-
dependent type 2 diabetes. Interestingly, serum levels of the
adipokine adiponectin were 20% lower in aged MT than in
aged CT, whereas those of leptin were similar (data not shown).
Upon an 8 week high fat diet (HFD) treatment that started at 5
weeks of age, the MT body weight was 35% higher in MT than
CT (Figure 3B). Moreover, after 8 weeks of HFD feeding, TG se-
rum levels were 25% higher in MT than in CT (Figure 3F), and MT
were more insulin-resistant than CT when subjected to an intra-
peritoneal insulin tolerance test (Figure 3G).
Discussion
Previous studies have suggested that PPARb could control skel-
etal muscle oxidative capacity and slow fiber-type formation in
mice (Luquet et al., 2003; Tanaka et al., 2003; Wang et al.,
2004). We show here that Cre recombinase-mediated selective
ablation of PPARb in skeletal muscle myocytes results in an age-
dependent reduction of muscle oxidative capacity and induces
a functional muscle fiber-type switching toward less oxidative fi-
bers. Importantly, the fiber-type switching precedes obesity and
diabetes and appears to be the cause and not the consequence
of these metabolic disorders. Indeed, even though glucose ho-
meostasis is impaired at an early time, only aged MT mice are
insulin resistant. Interestingly, serum adiponectin levels, known410to be decreased in insulin-resistant states (Kadowaki et al.,
2006), were also decreased in aged MT mice. Thus, whole-
body insulin resistance might appear when a critical fraction of
the SO fibers have been converted to FG fibers and/or after
reaching a ‘‘given stage’’ of obesity, when the levels of adipo-
kines known to play an important role in whole body insulin sen-
sitivity, are ‘‘altered’’ (Lazar, 2005). A similar decrease in muscle
oxidative capacity was obtained by PPARb ablation in skeletal
myocytes of adult mice, using transgenic mice expressing the
tamoxifen-dependent Cre-ERT2 recombinase under the skeletal
actin promoter (Schuler et al., 2005), thus demonstrating that
PPARb is instrumental in myocytes for the maintenance of their
oxidative capacity.
Exercise training is known to increase PPARb levels in skeletal
muscles (Luquet et al., 2003), and PPARb levels are higher in
slow-twitch oxidative than in fast-twitch glycolytic muscles in
mice (Wang et al., 2004). Our data therefore point to a mecha-
nism whereby increased levels of PPARb could be instrumental
in muscle fiber-type switch. PGC1a is known to play an impor-
tant role in the formation/maintenance of slow muscle fibers (Le-
one et al., 2005; Lin et al., 2005). PGC1a levels are higher in
slow-twitch oxidative than in fast-twitch glycolytic muscles in
mice, and exercise training increases muscle PGC1a levels via
a calcium signaling cascade, including calcineurin, calmodulin
dependent kinase IV (CaMKIV), myocyte enhancer factor 2
(MEF2), CREB, and nuclear factor of activated T cells (NFAT)
(Lin et al., 2005; see Figure 4E). Importantly, we found in the
mouse and human PGC1a promoter/enhancer region a con-
served PPRE that specifically binds PPARb/RXRa heterodimers
in vitro. Moreover, the PPARb-selective agonist GW 501516
stimulates the activity of the mouse PGC1a promoter through
this PPRE in C2C12 myocytes. In keeping with these findings,
PGC1a transcript levels are reduced in skeletal muscles of
PPARbskm2/2 mouse mutants (Figure 1I), and PPARb-selective
ligands enhance PGC1a transcript levels in mouse skeletal mus-
cles (Figure 2D; Tanaka et al., 2003). It appears therefore thatCELL METABOLISM : NOVEMBER 2006
PPARb function in skeletal muscles of the mouseCELL METABOLISM : NOVEMBER 2006liganded PPARb participates in the formation/maintenance of
slow muscle fiber type by stimulating PGC1a expression in mus-
cle cells (Figure 4E). However, it has been reported that PGC1a
levels are inversely correlated with intramuscular fatty acid
levels in rodents (Benton et al. [2006] and references therein)
and also that unsaturated but not saturated fatty-acids in-
creased PGC1a expression in differentiated myotubes (Staiger
et al., 2005). This suggests that in skeletal muscles the ligands
that activate PPARb are selected fatty acids or fatty-acid
metabolites.
Interestingly, as PGC1a is known to act as a PPARb coactiva-
tor (Dressel et al., 2003; Wang et al., 2003), the PGC1a promoter
activity can be enhanced through a feed-forward loop similar to
that resulting from the interaction of PGC1a with MEF2 (Hand-
schin et al., 2003), another transcriptional activator that binds
to the PGC1a promoter. Together, these two feed-forward loops
may ensure a stable transcription of PGC1a, leading to efficient
maintenance of slow fatigue-resistant muscle fibers, as well as
to sustained increase in muscle mitochondrial oxidation capac-
ity (Figure 4E). In this respect, we note that a recent report (Hon-
dares et al., 2006) has shown that the PGC1a gene is a direct tar-
get of PPARg in brown and white adipocytes, which suggests
that PGC1a expression could be differentially regulated in adi-
pocytes and myocytes.
In summary, our data demonstrate that PPARb is required in
skeletal muscles for the maintenance of slow oxidative fibers,
and that this effect is mediated, at least in part, through the con-
trol of expression of PGC1a at the transcriptional level. Further-
more, we have established that ablation of PPARb in mouse
skeletal muscles leads to obesity and diabetes. As physical ex-
ercise is known to result in a PPARb increase in skeletal mus-
cles, its beneficial effects in preventing obesity and diabetes
could be mediated, at least in part, through induction of PPARb
signaling at the level of the receptor and/or its cognate ligand(s).
Whether this induction is triggered by muscle contraction
through the calcium signaling cascade, as in the case of
PGC1a, remains to be investigated (Figure 4E).
Experimental procedures
Mice
Mice were maintained in a temperature- and humidity-controlled animal facil-
ity, with a 12 hr light/dark cycle and free access to water and a standard ro-
dent chow (2800 kcal/kg, Usine d’Alimentation Rationelle, Villemoisson-sur-
Orge, France). The HFD study was carried out with a chow containing 4,056
kcal/kg (fat: 1,600 kcal/kg and sucrose: 1,600 kcal/kg; research Diets, New
Brunswick, New Jersey). HFD was given to mice at weaning. Body weight
Figure 3. Increased adiposity in aging PPARbskm2/2 animals
A) Dorsal view of a 25 week-old regular diet fed CT and PPARbskm2/2 mouse.
B) Body weight gain of CT and PPARbskm2/2 mice fed a regular (RD) or high fat
(HFD) diet (n = 6–10) (RD cohorte: body weight at week 5: CT, 24 6 1.8 g; MT,
22.3 6 1.0 g; body weight gain between week 5 and 28: CT, 52%; MT, 88%;
HFD cohorte: HFD: body weight at week 5; CT, 19, 3 6 1.15 g; MT, 18.5 6 1.87
g, p = 0, 37; body weight gain between week 5 and 13: CT, 70%; MT, 105%).
C) Total body fat content in 17 week-old RD-fed CT and MT mice determined by
DEXA (n = 6–10).
D) Relative epidydimal, subcutaneous, and perirenal WAT weight of 28 week-old
RD-fed CT and MT mice.
E)Histology of epidydimal WAT of 28 week-old RD-fed CT and MT mice. Scale bar,
160 mm.
F) Serum triglyceride levels in 13 week-old HFD-fed CT and MT mice (n = 5).
G) Intraperitoneal insulin tolerance test in 13 week-old HFD-fed CT and MT mice
(n = 4–6).411
S H O R T A R T I C L EFigure 4. Impaired glucose homeostasis in PPARbskm2/2 mice and schematic
model of exercice-induced fiber type switching
A) Serum glucose, insulin and triglyceride levels in 12 week-old CT and MT mice
(n > 8).
B–D) Intraperitoneal insulin (B and C) and (D) glucose tolerance tests in 12 (B) and
32 (C and D) week-old mice (n = 4–6).
E) Schematic model of exercice-induced fiber-type switching. The PGC1a pro-
moter/enhancer region contains a PPRE, a MEF binding site (MEF-BS), and a
cAMP response element (CRE). Muscle contraction induces a calcium-signaling
pathway that activates CREB and MEF2 via CamKIV and calcineurinA (CnA) and
thus stimulates PGC1a promoter activity. Exercise increases PPARb levels
(through an unknown mechanism) and may also increase the level of PPARb li-
gands (fatty acids, FA). Increased PPARb activity further enhances PGC1a expres-
sion. Moreover, PGC1a by coactivating MEF2 and PPARb provides a positive
feed-forward signal to further increase PGC1a expression. In turn, PGC1a stimu-
lates the expression of NRF1 and NRF2, thus leading to enhanced expression of412was determined at the indicated ages, and body-fat content was evaluated in
anaesthetized mice by dual X-ray absorptiometry (DEXA; PIXIMUS, GE Med-
ical Systems, Buc, France). Blood was collected from the retroorbital sinus
after a 6 hr fast that started at the beginning of the light cycle, and serum glu-
cose, insulin, and triglycerides levels were analyzed as described (Picard
et al., 2002). Insulin and glucose tolerance tests were performed on 3 and
8–9 month-old mice that were fasted for 3 hr. Glucose concentrations were
determined with a OneTouch blood glucometer (LifeScan, Lissy les Mouli-
neaux, France) in blood collected from the tail vein before (0 min) and 15, 30,
60, and 90 min after intraperitoneal injection of insulin (1 U/kg, bovine insulin
from Sigma) or glucose (2g/kg).
Animals were killed by CO2 inhalation at the beginning of the light cycle,
and tissues were collected, weighed, and frozen in liquid nitrogen or pro-
cessed for biochemical and histological analysis.
Histological and histochemical analysis
Muscles were quickly frozen in dry ice-cooled isopentane. For NADH-tetra-
zolium reductase staining, 10 mm cryosections were incubated in 0.2 M
Tris, pH 7.4, containing 1.5 mM NADH and 1.5 mM nitrobluetetrazolium for
15 min at 55C, dehydrated, and mounted. SO and FOG fibers are positively
stained, whereas FG fibers remain unstained (Hamalainen and Pette, 1993).
Epididymal WAT was fixed in Bouin’s solution, dehydrated in ethanol, em-
bedded in paraffin, and cut at a thickness of 10 mm. Sections were deparaffi-
nized, rehydrated, and stained with haematoxylin and eosin.
Electrophoretic mobility shift assays
pSG5-based PPARb and RXRa expression plasmids were in vitro tran-
scribed/translated using the TnT Quick coupled transcription/translation
system according to the manufacturer’s recommendations (Promega).
EMSAs were performed as described (Rochette-Egly et al., 1994), using
0.05 pmol of end-labeled oligonucleotide pairs. The PGC1a-PPRE and the
PGC1a-PPREm were obtained by annealing oligonucleotides 50-GATC
CAAAATTCAGGACAAAGGTCAG-30 and 50-GATCCTGACCCTTTGTTCCC
CTGAATTTTG-30, and 50-AGCCCATGAGGTTTGTGGTGAATTTTAATA-30
and 50-TATTAAAATTCACCACAAACCTCATGGGCT-30, respectively. Unla-
beled oligonucleotide pairs were added to the binding reaction for competi-
tion experiments.
Cell culture and transfection assays
5.104 C2C12 myoblasts were seeded in 24-well plates and grown for 24 hr in
proliferation medium (Dulbecco’s modified Eagle medium [DMEM]; glucose,
1 g/l, supplemented with 20% delipidated FCS). 0.2 mg pCMV-bgal and
0.8 mg pGL-PGC1a, pGL-PGC1am or pGL3-basic (see Supplemental Data)
was mixed with 3 ml of Fugene6 transfection reagent (Roche Diagnostics)
in 100 ml DMEM, according to the supplier’s protocol. After 15 min at room
temperature, 30 ml transfection mix was added to each well, and the medium
was changed 7 hr later to differentiation medium (DMEM supplemented with
5% delipidated FCS), containing the PPARa ligand Wy 14643 (10 mM), the
PPARb ligand GW501516 (1 mM), or the PPARg ligand rosiglitazone
(50 mM). Sixteen hours later, cells were harvested, lysed, and assayed for
b-galactosidase (Voegel et al., 1998) and luciferase activity (Promega).
Each transfection was done in triplicate. Luciferase activity was normalized
to the b-galactosidase activity, and data are expressed as fold difference
relative to the normalized luciferase activity of pGL3-basic transfection in
the absence ligand, which was set as 1.
For RNA preparation, 3.105 C2C12 myoblasts were seeded in 6-well plates
and grown for 30 hr in proliferation medium supplemented with 20% delipi-
dated FCS. The medium was changed 30 hr later to differentiation medium,
containing 1 mM GW501516 and 10 mM BMS961 or vehicle, and cells were
harvested 16 hr later.
Data analysis
Data are presented as mean 6 SEM. Differences analyzed by a two-tailed
Student’s t test were considered statistically significant at p < 0.05 and are
indicated by an asterisk in the figures.
nuclear-encoded mitochondrial genes. PGC1a simultaneously regulates the
switch to slow-twitch muscle fiber genes through coactivation of MEF2. PPARb/
RXR heterodimers also stimulate the expression of genes involved in fatty acid
uptake and b-oxidation, and PGC1a may potentiate it.CELL METABOLISM : NOVEMBER 2006
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